Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis

开发新型 MetAP2 抑制剂作为微孢子虫病的潜在疗法

基本信息

项目摘要

Abstract This application represents an approach to rational drug design for the treatment of microsporidiosis using structure activity relationships (SAR) for agents that inhibit Methionine Aminopeptidase type 2 (MetAP2). Microsporidiosis is an emerging zoonotic infection that is an opportunistic pathogen in the setting of AIDS, but is also seen in other immune compromised hosts as well as immune competent hosts. Current therapies are suboptimal. The hypothesis underlying this type of grant is that differences in the structure of the drug target between host and pathogen will permit the design of selective therapeutic agents with decreased host toxicity. The initial choice in drug design is the selection of the target among the dozens of potential targets. MetAP2 is an extremely logical therapeutic target for these pathogens. Microsporidia lack Methionine Aminopeptidase type 1 (MetAP1) making MetAP2 an essential enzyme. Among eukaryotes this makes them highly susceptible to MetAP2 inhibitors and limits the toxicity of these compounds in their hosts as humans have both MetAP1 and MetAP2. Use of Fumagillin and its derivatives, which are non-competitive inhibitors that covalently bind to and inhibit MetAP2 (but not MetAP1), has confirmed that inhibition of MetAP2 is an effective in vitro and in vivo therapeutic target for many species of microsporidia. In fact, Fumagillin has been demonstrated to have efficacy in humans infected with Enterocytozoon bieneusi; however, its use has been limited by bone marrow toxicity. Our research group has cloned, expressed and determined the crystal structure of the MetAP2 of the microsporidian Encephalitozoon cuniculi (i.e. EcMetAP2) as well as developed yeast dependent on EcMetAP2 for growth. We have identified and cloned Ent.bieneusi MetAP2 (EbMetAP2). Exploiting differences in the structure of MetAP2 between host and pathogen should permit the design of selective therapeutic competitive inhibitors of MetAP2 with decreased host toxicity. These new inhibitors will be tested in vitro and in vivo for efficacy and in an iterative process we will use this information to refine our models and improve inhibitor design. Using this Limited Rational Design (LRD) approach we will generate new libraries based on our lead compounds that will then be modified to generate new libraries to improve their selectivity and pharmacologic properties. We have already identified two lead compounds, BL6 and D63, from our initial LRD/SAR studies that have increased selectivity for microsporidian MetAP2 and efficacy in our in vitro and in vivo models of microsporidiosis. Since MetAP2 is important in other protozoa our lead compounds should also define new classes of drugs that could have broad anti-parasitic activity and prove useful in the treatment of other infections. Our assembled research group containing experts in medicinal chemistry, parasitology, bioinformatics, mass spectrometry and structural biology as well as industry consultants has the necessary complementary expertise to develop and test these compounds.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bhaskar Chandra Das其他文献

Bhaskar Chandra Das的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bhaskar Chandra Das', 18)}}的其他基金

Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol Exposure
受体特异性视黄醇探针用于研究发育期酒精暴露引起的脑损伤
  • 批准号:
    10203693
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis
开发新型 MetAP2 抑制剂作为微孢子虫病的潜在疗法
  • 批准号:
    10381678
  • 财政年份:
    2018
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis
开发新型 MetAP2 抑制剂作为微孢子虫病的潜在疗法
  • 批准号:
    10214531
  • 财政年份:
    2018
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis
开发新型 MetAP2 抑制剂作为微孢子虫病的潜在疗法
  • 批准号:
    10183071
  • 财政年份:
    2018
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)
肝细胞生长因子(HGF)小分子模拟物的开发
  • 批准号:
    8669490
  • 财政年份:
    2011
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)
肝细胞生长因子(HGF)小分子模拟物的开发
  • 批准号:
    8166335
  • 财政年份:
    2011
  • 资助金额:
    $ 39万
  • 项目类别:
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)
肝细胞生长因子(HGF)小分子模拟物的开发
  • 批准号:
    8452875
  • 财政年份:
    2011
  • 资助金额:
    $ 39万
  • 项目类别:

相似海外基金

Selective inhibitors of Heme Transporters as Antiparasitic Agents
作为抗寄生虫剂的血红素转运蛋白选择性抑制剂
  • 批准号:
    8901577
  • 财政年份:
    2015
  • 资助金额:
    $ 39万
  • 项目类别:
Simple, Selective Antimitotic Antiparasitic Agents
简单、选择性抗有丝分裂抗寄生虫药
  • 批准号:
    7086168
  • 财政年份:
    2004
  • 资助金额:
    $ 39万
  • 项目类别:
Simple, Selective Antimitotic Antiparasitic Agents
简单、选择性抗有丝分裂抗寄生虫药
  • 批准号:
    7245023
  • 财政年份:
    2004
  • 资助金额:
    $ 39万
  • 项目类别:
Simple, Selective Antimitotic Antiparasitic Agents
简单、选择性抗有丝分裂抗寄生虫药
  • 批准号:
    6813915
  • 财政年份:
    2004
  • 资助金额:
    $ 39万
  • 项目类别:
Simple, Selective Antimitotic Antiparasitic Agents
简单、选择性抗有丝分裂抗寄生虫药
  • 批准号:
    6909861
  • 财政年份:
    2004
  • 资助金额:
    $ 39万
  • 项目类别:
STRUCTURE-BASED DESIGN OF ANTIPARASITIC AGENTS
基于结构的抗寄生虫剂设计
  • 批准号:
    6372898
  • 财政年份:
    2001
  • 资助金额:
    $ 39万
  • 项目类别:
STRUCTURE-BASED DESIGN OF ANTIPARASITIC AGENTS
基于结构的抗寄生虫剂设计
  • 批准号:
    6169115
  • 财政年份:
    2000
  • 资助金额:
    $ 39万
  • 项目类别:
STRUCTURE-BASED DESIGN OF ANTIPARASITIC AGENTS
基于结构的抗寄生虫剂设计
  • 批准号:
    2861264
  • 财政年份:
    1999
  • 资助金额:
    $ 39万
  • 项目类别:
Antiparasitic Agents from Wild Primate Medicinal Plants
来自野生灵长类药用植物的抗寄生虫剂
  • 批准号:
    06044122
  • 财政年份:
    1994
  • 资助金额:
    $ 39万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
MORPHOLINO-ANTISENSE POLYMERS AS ANTIPARASITIC AGENTS
吗啉代反义聚合物作为抗寄生虫剂
  • 批准号:
    2069304
  • 财政年份:
    1993
  • 资助金额:
    $ 39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了